MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

September 23, 2021

Study Completion Date

December 1, 2025

Conditions

Lung Carcinoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

MUC1 Peptide-Poly-ICLC Vaccine

Given SC

Trial Locations (2)

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

Mayo Clinic in Rochester, Rochester

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH